Aduro Clean Technologies gibt Abschluss des Uplistings in Höhe von 4 Mio. USD an der Nasdaq bekannt
November 09, 2024 15:41 ET
|
Aduro Clean Technologies Inc.
LONDON, Ontario, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. („Aduro“ oder das „Unternehmen“) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), ein Unternehmen für saubere Technologien, das...
Aduro Clean Technologies annonce la clôture de sa cotation au Nasdaq pour un montant de 4 millions de dollars
November 09, 2024 15:41 ET
|
Aduro Clean Technologies Inc.
LONDON, Province de l’Ontario, 09 nov. 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc., ci-après « Aduro » ou la « Société » (Nasdaq : ADUR) (CSE : ACT) (FSE : 9D5), une société de...
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
November 09, 2024 13:40 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of...
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 09, 2024 13:30 ET
|
Fate Therapeutics, Inc.
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows...
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET
|
Replimune Group Inc
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration,...
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
November 09, 2024 10:30 ET
|
Ultragenyx Pharmaceutical Inc.
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by...
Mission Produce® Implements Policy Addressing Illegal Deforestation
November 08, 2024 20:00 ET
|
Mission Produce, Inc.
OXNARD, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today...
AppLovin Corporation to Join the Nasdaq-100 Index® Beginning November 18, 2024
November 08, 2024 20:00 ET
|
Nasdaq, Inc.
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that AppLovin Corporation (Nasdaq: APP), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX®) and the...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024 17:30 ET
|
InspireMD, Inc.
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation...
Lucas GC Limited Announces Status of US$6 Million Share Repurchase Program
November 08, 2024 17:00 ET
|
Lucas GC Limited
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Lucas GC Limited (NASDAQ: LGCL) (“Lucas” or the “Company”), an artificial intelligence (the “AI”) technology-driven Platform-as-a-Service (the “PaaS”)...